A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) (iDEAL)
This study is ongoing, but not recruiting participants.
Quan Dong Nguyen
Juvenile Diabetes Research Foundation
iCo Therapeutics Inc.
Information provided by (Responsible Party):
Quan Dong Nguyen, Johns Hopkins University
First received: March 15, 2012
Last updated: June 24, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||December 2013|
|Estimated Primary Completion Date:||September 2013 (Final data collection date for primary outcome measure)|